John Harrison
John Harrison
Associate Professor, VUmc
Verified email at - Homepage
Cited by
Cited by
Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial
L Lannfelt, K Blennow, H Zetterberg, S Batsman, D Ames, J Harrison, ...
The Lancet Neurology 7 (9), 779-786, 2008
Synaesthesia: prevalence and familiality
S Baron-Cohen, L Burt, F Smith-Laittan, J Harrison, P Bolton
Perception 25 (9), 1073-1079, 1996
S Baron-Cohen, J Harrison
Encyclopedia of cognitive science, 295-301, 1997
PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses
NG Faux, CW Ritchie, A Gunn, A Rembach, A Tsatsanis, J Bedo, ...
Journal of Alzheimer's Disease 20 (2), 509-516, 2010
Coloured speech perception: Is synaesthesia what happens when modularity breaks down?
S Baron-Cohen, J Harrison, LH Goldstein, M Wyke
Perception 22 (4), 419-426, 1993
The physiology of coloured hearing A PET activation study of colour-word synaesthesia
E Paulesu, J Harrison, S Baron-Cohen, JDG Watson, L Goldstein, ...
Brain 118 (3), 661-676, 1995
Efficacy of Souvenaid in mild Alzheimer's disease: results from a randomized, controlled trial
P Scheltens, JWR Twisk, R Blesa, E Scarpini, CAF von Arnim, A Bongers, ...
Journal of Alzheimer's Disease 31 (1), 225-236, 2012
Serial reaction time learning and Parkinson's disease: Evidence for a procedural learning deficit
GM Jackson, SR Jackson, J Harrison, L Henderson, C Kennard
Neuropsychologia 33 (5), 577-593, 1995
Synaesthesia: The strangest thing
JE Harrison
Oxford University Press, 2001
Short test of semantic and phonological fluency: Normal performance, validity and test‐retest reliability
JE Harrison, P Buxton, M Husain, R Wise
British Journal of Clinical Psychology 39 (2), 181-191, 2000
Cognitive impairment associated with cancer: a brief review
JC Pendergrass, SD Targum, JE Harrison
Innovations in Clinical Neuroscience 15 (1-2), 36, 2018
A neuropsychological test battery for use in Alzheimer disease clinical trials
J Harrison, SL Minassian, L Jenkins, RS Black, M Koller, M Grundman
Archives of neurology 64 (9), 1323-1329, 2007
The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease
M Colom-Cadena, T Spires-Jones, H Zetterberg, K Blennow, A Caggiano, ...
Alzheimer's research & therapy 12, 1-12, 2020
The effects of vortioxetine on cognitive function in patients with major depressive disorder: a meta-analysis of three randomized controlled trials
RS McIntyre, J Harrison, H Loft, W Jacobson, CK Olsen
International Journal of Neuropsychopharmacology 19 (10), pyw055, 2016
Detecting cognitive changes in preclinical Alzheimer's disease: A review of its feasibility
M Mortamais, JA Ash, J Harrison, J Kaye, J Kramer, C Randolph, C Pose, ...
Alzheimer's & dementia 13 (4), 468-492, 2017
Saccadic eye movement and working memory deficits following damage to human prefrontal cortex
R Walker, M Husain, TL Hodgson, J Harrison, C Kennard
Neuropsychologia 36 (11), 1141-1159, 1998
Cerebral areas associated with motor control of speech in humans
K Murphy, DR Corfield, A Guz, GR Fink, RJS Wise, J Harrison, L Adams
Journal of applied physiology 83 (5), 1438-1447, 1997
Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer’s disease: study protocol for a randomised controlled trial (ELAD study)
GD Femminella, E Frangou, SB Love, G Busza, C Holmes, C Ritchie, ...
Trials 20, 1-10, 2019
Mobile health interventions to promote physical activity and reduce sedentary behaviour in the workplace: a systematic review
SA Buckingham, AJ Williams, K Morrissey, L Price, J Harrison
Digital health 5, 2055207619839883, 2019
The THINC-integrated tool (THINC-it) screening assessment for cognitive dysfunction: validation in patients with major depressive disorder
RS McIntyre, MW Best, CR Bowie, NE Carmona, DS Cha, Y Lee, ...
The Journal of clinical psychiatry 78 (7), 873-881, 2017
The system can't perform the operation now. Try again later.
Articles 1–20